

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

SUPPLEMENTARY INFORMATION

Critical timing for triggering public health interventions to prevent COVID-19 resurgence: a mathematical modelling study

Zhuoru Zou¹, Christopher K Fairley¹⁻³, Mingwang Shen¹, Nick Scott⁵, Xianglong Xu¹⁻³, Zengbing Li¹, Rui Li¹, Guihua Zhuang^{1*}, Lei Zhang^{1-4*}

1. China-Australia Joint Research Centre for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, China
2. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia
3. Central Clinical School, Faculty of Medicine, Monash University, Melbourne, Australia
4. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China
5. Burnet Institute, Melbourne, Australia

*Equal contribute to supervision

Corresponding authors:


Prof. Lei Zhang. PhD. China-Australia Joint Research Centre for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, China, E-mail: lei.zhang1@monash.edu

Prof. Guihua Zhuang. PhD. China-Australia Joint Research Centre for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, China, E-mail: zhuanggh@mail.xjtu.edu.cn

1. Model equations and detailed description

1.1 Model Structure

We constructed a dynamic compartmental model to describe the spread of SARS-CoV-2 and the impact of public health interventions. The population is divided into ten compartments (Supplementary Fig. 1): susceptible individuals (S), asymptomatic infections (A), pre-symptomatic infections (E), symptomatic infections before diagnosis (I), diagnosed individuals with isolation and treatment (T), uninfected individuals among the quarantined close contacts (Q_S), infected individuals among the quarantined close contacts (Q_{EA}), vaccinated individuals (V), recovered individuals (R), and dead individuals (D). The total population size is denoted by N, where $N = S + A + E + I + T + Q_S + Q_{EA} + V + R$.



Supplementary Fig. 1 A schematic flow diagram of the transmission of SARS-CoV-2

1.2 Model equations

The model is described by the following system of ordinary differential equations. The symbols are defined in the legend following the equations.

$$\begin{aligned}
 \dot{S} &= -\Lambda_I^{total} - \Lambda_E^{total} - \Lambda_A^{total} - Cont_{non-infection} \cdot \xi - \tau \cdot S - \theta \cdot p \cdot S + g \cdot Q_S \\
 \dot{A} &= (\Lambda_I^{total} + \Lambda_E^{total} + \Lambda_A^{total}) \cdot \psi - r_1 \cdot A - Cont_{infection} \cdot \psi \cdot \xi - \tau \cdot A \\
 \dot{E} &= (\Lambda_I^{total} + \Lambda_E^{total} + \Lambda_A^{total}) \cdot (1 - \psi) - v \cdot E - Cont_{infection} \cdot (1 - \psi) \cdot \xi - \tau \cdot E \\
 \dot{I} &= v \cdot E - q \cdot I \\
 \dot{Q}_S &= Cont_{non-infection} \cdot \xi + \tau \cdot S - g \cdot Q_S \\
 \dot{Q}_{EA} &= Cont_{infection} \cdot \xi + \tau \cdot (E + A) - g \cdot Q_{EA} \\
 \dot{T} &= q \cdot I + g \cdot Q_{EA} - r_2 \cdot T - \mu \cdot T \\
 \dot{R} &= r_1 \cdot A + r_2 \cdot T \\
 \dot{D} &= \mu \cdot T
 \end{aligned} \tag{1}$$

Parameters in the differential equations:

Compartments symbols	Description
S	Susceptible individuals
A	Asymptomatic infected individuals (cases who never developed any noticeable symptoms during the entire period of their disease)
E	Pre-symptomatic infected individuals (cases who have mild symptoms before the onset of symptoms)
I	Symptomatic but undiagnosed individuals
Q_S	Uninfected individuals among the quarantined close contacts
Q_{EA}	Infected individuals among the quarantined close contacts
T	Diagnosed individuals with isolation and treatment
R	Recovered individuals
D	Individuals who died from COVID-19-related complications
Parameter symbols	Description
Λ_I^{total}	Probability of being infected by exposure to symptomatic infected individuals (I) in public places and households
Λ_E^{total}	Probability of being infected by exposure to pre-symptomatic infected individuals (E) in public places and households
Λ_A^{total}	Probability of being infected by exposure to asymptomatic infected individuals (A) in public places and households
ψ	The proportion of asymptomatic infections among newly infected individuals
$1/v$	The mean incubation time (days)
$1/q$	The interval from symptom onset to isolation in hospital or quarantine (days)
$1/g$	The interval from testing to diagnosis (days)
$1/r_1$	The mean time from infection to recovery for asymptomatic infected individuals (days)
$1/r_2$	The mean time from diagnosis to recovery for symptomatic infected individuals (days)
μ	Disease-induced death rate
$Cont_{non-infection}$	Uninfected close contacts of the daily new confirmed cases
$Cont_{infection}$	Infected close contacts of the daily new confirmed cases
ξ	Effectiveness of contact tracing
τ	The coverage rate of voluntary testing
θ	Efficacy of the COVID-19 vaccine
p	The coverage rate of COVID-19 vaccination

55

56 **1.3 Modelling disease progression**

57 Newly infected individuals would enter the asymptomatic infection compartment (A) and the pre-
58 symptomatic infection compartment (E) according to the proportions ψ ($0 \leq \psi \leq 1$) and $(1 - \psi)$,
59 respectively. In the absence of any public health intervention, asymptomatic infected individuals (A)
60 were assumed to recover naturally at the rate r_1 . Individuals in the incubation period (E) would
61 progress to the symptomatic infection compartment (I) at the rate v . Symptomatic infected
62 individuals (I) were assumed to be diagnosed at the rate q and enter the treatment compartment (T)

63 and then be isolated and treated. We also assumed strict isolation so that isolated individuals could
 64 not further infect others. Treated individuals would recover at the rate r_2 or die due to the disease
 65 at the rate μ .

66

67 **1.4 Force of infection, social distancing, and face mask use**

68 Susceptible individuals may be infected through contact with undocumented cases (sources of
 69 infection), including asymptomatic infected individuals (A), pre-symptomatic infected individuals
 70 (E), and symptomatic but undiagnosed individuals (I). Force of infection (Λ^{total}) is given by the
 71 sum of probabilities of being infected by exposure to undocumented cases. That is,

$$\Lambda^{total} = \Lambda_A^{total} + \Lambda_E^{total} + \Lambda_I^{total} \quad (2)$$

72

73 Transmission may occur in public places and households. Thus, the probability of being infected by
 74 exposure to asymptomatic infected individuals (Λ_A^{total}), for example, is the sum of probabilities
 75 from these two routes. It can be expressed as:

$$\begin{aligned} \Lambda_A^{total} &= \Lambda_A^{fam} + \Lambda_A^{pub} = \beta_{EA}^{fam} \cdot \frac{A}{N_f} \cdot S + \beta_{EA}^{pub} \cdot c_p(t) \cdot \frac{A}{N} \cdot S \\ \Lambda_E^{total} &= \Lambda_E^{fam} + \Lambda_E^{pub} = \beta_{EA}^{fam} \cdot \frac{E}{N_f} \cdot S + \beta_{EA}^{pub} \cdot c_p(t) \cdot \frac{E}{N} \cdot S \\ \Lambda_I^{total} &= \Lambda_I^{fam} + \Lambda_I^{pub} = \beta_I^{fam} \cdot \frac{I}{N_f} \cdot S + \beta_I^{pub} \cdot c_p(t) \cdot \frac{I}{N} \cdot S \end{aligned} \quad (3)$$

76 Where,

$$\begin{aligned} \beta_I^{fam} &= \beta, & \beta_I^{pub} &= \beta \cdot (1 - \rho) \cdot (1 - \sigma \cdot m(t)) \\ \beta_{EA}^{fam} &= \beta_I^{fam} \cdot (1 - \varepsilon), & \beta_{EA}^{pub} &= \beta_I^{pub} \cdot (1 - \varepsilon) \end{aligned} \quad (4)$$

77

78 Using the example of being infected by asymptomatic infected individuals (Λ_A^{total}), for household
 79 exposure, the probability of being infected (Λ_A^{fam}) is equal to the risk of coming from a household
 80 with an asymptomatic infected individual ($\frac{A}{N_f}$) multiplied by the average daily probability of being

81 infected in the household (β_A^{fam}); for public places exposure, the probability of being infected (Λ_A^{pub})

82 is equal to the probability of being exposed to a person who is an asymptomatic infected individual

83 ($\frac{A}{N}$) multiplied by the average daily probability of being infected by contact with an asymptomatic

84 infected individual in public places (β_A^{pub}), and multiplied by the average number of contacts in

85 public places per day ($c_p(t)$). Social distancing restrictions will affect $c_p(t)$ and thus prevent

86 infection.

87

88 Here N_f denotes the total number of households, which is equal to the total population size (N)

89 divided by the average household size (c_f) in Australia. We assumed that undocumented cases are

90 dispersed among different households. Because the prevalence of COVID-19 in Australia is low

91 and the probability of two or more household members being infected simultaneously in various

92 public venues is small. We abbreviated the average daily probability of being infected by contact

93 with the symptomatic infected individual in the household (β_I^{fam}) as β . Usually, the average

94 frequency of daily person-to-person contacts in public places is less than that within the home. We,
 95 therefore, assumed that the average daily probability of being infected by contact with a
 96 symptomatic infected individual in a public place (β_I^{pub}) is less than that of being infected by contact
 97 with a symptomatic infected individual at home (β_I^{fam}), and denoted the percentage reduction as ρ
 98 ($0 \leq \rho \leq 1$). The parameters σ and $m(t)$ denote the effectiveness and coverage rate of face mask
 99 use in public places, respectively, which reflect the effect of face mask use on infection prevention.
 100 We assumed that for contacts with asymptomatic/pre-symptomatic infected individuals, the average
 101 probability of being infected is lower, i.e. $(1 - \varepsilon) \cdot \beta$ where $0 \leq \varepsilon \leq 1$ denotes the reduction in daily
 102 transmission probability.

103

104 1.5 Contact tracing

105 The number of close contacts of newly diagnosed cases in public places and households was
 106 calculated based on the following formula:

$$\begin{aligned}
 Cont_I^{fam} &= I \cdot q \cdot (c_f - 1) \\
 Cont_I^{pub} &= I \cdot q \cdot c_p(t) \cdot t_1 \\
 Cont_{EA}^{fam} &= Q_{EA} \cdot g \cdot (c_f - 1) \\
 Cont_{EA}^{pub} &= Q_{EA} \cdot g \cdot c_p(t) \cdot t_2
 \end{aligned} \tag{5}$$

107

108 Where $Cont_I^{fam}$ and $Cont_I^{pub}$ indicate the total number of close contacts in households and
 109 public places for new cases diagnosed due to symptoms. Similarly, $Cont_{EA}^{fam}$ and $Cont_{EA}^{pub}$
 110 indicate the total number of close contacts in households and public places for new
 111 asymptomatic/pre-symptomatic cases diagnosed due to testing and quarantine. The total number of
 112 close contacts was estimated by multiplying the number of new diagnoses by the average number
 113 of close contacts per individual. $I \cdot q$ and $Q_{EA} \cdot g$ denote the number of daily new diagnosed cases
 114 detected from symptomatic infected individuals and asymptomatic/pre-symptomatic infected
 115 individuals, respectively. For each confirmed case, the number of close contacts from the household
 116 is the number of family members other than the case, i.e., $c_f - 1$; the number of close contacts from
 117 public places is the product of the average daily number of close contacts in public places ($c_p(t)$)
 118 and the number of tracing days. The parameters t_1 and t_2 represent the number of tracing days
 119 for symptomatic cases and asymptomatic/pre-symptomatic cases. According to the CDC¹, "an
 120 infected person can spread SARS-CoV-2 starting from 2 days before they have any symptoms (or,
 121 for asymptomatic patients, two days before the positive specimen collection date) until they meet
 122 the criteria for discontinuing home isolation". Thus, we assumed that t_1 is equal to the interval from
 123 symptom onset to isolation in the hospital ($1/q$) plus two days; t_2 is equal to two days.

124

125 We estimated the number of infected close contacts ($Cont_{infection}$) and uninfected close contacts
 126 ($Cont_{non-infection}$) according to the force of infection, expressed as:

$$\begin{aligned}
 Cont_{infection} &= \\
 &\beta_I^{fam} \cdot Cont_I^{fam} + \beta_I^{pub} \cdot \frac{1}{t_1} \cdot Cont_I^{pub} + \beta_{EA}^{fam} \cdot Cont_{EA}^{fam} + \beta_{EA}^{pub} \cdot \frac{1}{t_2} \cdot Cont_{EA}^{pub} \tag{6}
 \end{aligned}$$

$$\begin{aligned}
& Cont_{non-infection} = \\
& (1 - \beta_I^{fam}) \cdot Cont_I^{fam} + (1 - \beta_I^{pub}) \cdot \frac{1}{t_1} \cdot Cont_I^{pub} + (1 - \beta_{EA}^{fam}) \cdot Cont_{EA}^{fam} + \\
& (1 - \beta_{EA}^{pub}) \cdot \frac{1}{t_2} \cdot Cont_{EA}^{pub}
\end{aligned}$$

127

128 $(\beta_I^{fam} \cdot Cont_I^{fam} + \beta_{EA}^{fam} \cdot Cont_{EA}^{fam})$ denote the average daily number of infected close contacts

129 in households and $(\beta_I^{pub} \cdot \frac{1}{t_1} \cdot Cont_I^{pub} + \beta_{EA}^{pub} \cdot \frac{1}{t_2} \cdot Cont_{EA}^{pub})$ denote the average daily number of

130 infected close contacts in public places.

131

132 Depending on the effectiveness of contact tracing (i.e., the ability to detect and quarantine all close

133 contacts, denoted as ξ), a proportion of infected close contacts ($Cont_{infection} \cdot \xi$) would be

134 diagnosed and isolated, while a proportion of uninfected close contacts ($Cont_{non-infection} \cdot \xi$)

135 would be tested and quarantined but later returned to the susceptible compartment. The parameter

136 ξ may depend on various factors, such as willingness to cooperate, recall bias, availability of

137 contact tracers, and quarantine compliance. Previous reports have indicated that 20% of the close

138 contacts would be uncooperative, and among those who cooperate, 60% of recollected information

139 may be incorrect^{2,3}. Also, a further 20% of close contacts would likely fail to comply with

140 quarantine². Considering the above unavoidable factors, we estimated that the proportion of

141 remaining close contacts who could be detected and isolated through the capability of contact

142 tracing would be about 80% in Australia through model calibration.

143

144 1.6 Voluntary testing and vaccination

145 Voluntary testing was given to individuals who believed they were in close contact with infected

146 individuals and may be at risk of infection. We assumed that a proportion of individuals would be

147 voluntarily tested according to the coverage rate (denoted as τ). Susceptible individuals (S) who

148 have undergone voluntary testing would return to the susceptible compartment (S) after the testing

149 to diagnosis interval. In contrast, asymptomatic/pre-symptomatic infected individuals who have

150 undergone voluntary testing would be diagnosed after the testing to diagnosis interval and thus

151 strictly isolated.

152

153 Vaccination would reduce the proportion of susceptible individuals in the population. Individuals

154 who have been vaccinated and have developed immune protection would enter the vaccination

155 compartment (V). We assumed that this population would not be able to be infected in the short

156 term.

157

158 2. Data and parameter estimation

159 2.1 Epidemiological data

160 We searched historical outbreak data for COVID-19 from the official website of the Australian

161 Department of Health for the period 25 January 2020 to 12 March 2021, including the number of

162 daily reported cases (both with known and unknown sources), cumulative confirmed cases, and


163 deaths. Because some states and territories did not report information on the source of confirmed

164 cases (e.g., whether cases were from known clusters), satisfactory data from Victoria, New South
165 Wales, the Australian Capital Territory, and Western Australia were collected for analysis. We
166 calibrated the model with relevant data from Victoria. Further, we verified the reliability of the
167 model outputs with relevant data from New South Wales, the Australian Capital Territory, and
168 Western Australia, respectively.

169

170 The epidemiological data from the four states mentioned above were presented in Supplementary
171 Fig. 2. Confirmed cases are classified according to their source as overseas cases, locally known
172 cases and locally unknown cases. From 16 March 2020, all arrivals in Australia were required to be
173 in self-imposed isolation for 14 days, which became mandatory from 28 March 2020. Therefore,
174 we considered that the activity of overseas cases was unrestricted until 16 March 2020, and overseas
175 cases had the same potential for community transmission as locally acquired cases of known sources.
176 We assumed that 50% of overseas cases might comply with strict isolation between 17 March 2020
177 and 28 March 2020. We also assumed that all overseas cases might be in strict isolation after 29
178 March 2020, so they contributed only to the number of cases but not community transmission.


179



180

181 **Supplementary Fig. 2. COVID-19 epidemiological data and public health interventions in four Australian states (25 January 2020 – 12 March 2021)**

182 Supplementary Fig. 3 illustrated the proportion of daily unknown-source cases to total daily locally
 183 acquired cases in the historical outbreaks in the four states. We found that about 20% of locally
 184 acquired cases in Australia were of unknown sources. This proportion had large fluctuations,
 185 especially when the number of daily cases was low.
 186



187

188 **Supplementary Fig. 3 The proportion of unknown-source cases to total locally acquired**
 189 **cases in historical outbreaks in four Australian states**


190

191 **2.2 Data related to public health interventions**

192 **(1) Reduction in social activity and average number of daily close contacts**

193 The core elements and timelines of relevant public health policies implemented by each Australian
 194 state to control the spread of SARS-CoV-2 were collected and presented in Supplementary Fig. 2.
 195 To assess the impact of social distancing restrictions on social activities, we analyzed Google
 196 COVID-19 community mobility data and obtained changes in mobility in public places⁴. We
 197 expressed mobility changes as proportional deviations from levels for the baseline (Supplementary
 198 Fig. 4). It can be seen that policies influenced mobility in public places and that mobility decreased
 199 as restrictions were imposed and increased as restrictions were relaxed.

200



201

202 **Supplementary Fig. 4 Social activity changes and face mask coverage rates in four**
 203 **Australian states (25 January 2020 – 12 March 2021)**

204

205 We estimated that the average daily number of close contacts for individuals in public places in
 206 Australia without social distancing restrictions was 19, based on previous reports⁵. Further, we
 207 estimated the real-time average daily number of close contacts in public places based on the mobility
 208 changes in public places to simulate the impact of social distancing restrictions. According to the
 209 Australian Bureau of Statistics, the average household size is three. Therefore, the average number
 210 of close contacts in a household was estimated to be two.

211

212 **(2) Effectiveness and coverage rate of face mask use**

213 The effectiveness of face mask use in preventing infection was estimated to be 85% (95% CI: 50–
 214 95%), based on relevant meta-analysis against COVID-19^{6,7}. In the context of the COVID-19
 215 pandemic, the rate of face mask use in public places in Australia is around 10–30%, according to
 216 the report from the global health research centre at the University of Washington⁸. We assumed that
 217 face mask use in public places would increase spontaneously to about 50% when the lockdown was
 218 implemented. During mandatory face mask measures in Victoria, the face mask coverage in public
 219 places was estimated to reach 80–100%. The ranges of face mask coverage rates over time were
 220 estimated based on the relevant public health policies and were displayed in Supplementary Fig. 4.

221

222 **(3) Effectiveness of contact tracing, rate of voluntary testing and vaccine efficacy**

223 The effectiveness of contact tracing may depend on various factors, such as willingness to cooperate,
 224 recall bias, availability of contact tracers, and quarantine compliance. We estimated that 20% of the
 225 close contacts would be uncooperative, and among those who cooperate, 60% of recollected
 226 information may be incorrect^{2,3}. A further 20% of close contacts would likely fail to comply with
 227 quarantine². We estimated that approximately 80% of close contacts among the remaining close
 228 contacts (cooperative and without recall bias) would be detected and isolated in Australia using
 229 model calibration.

230

231 Based on the cumulative number of COVID-19 voluntary tests over the past 7 days and the
232 population size reported by the Australian Government Department of Health, we estimated that
233 0.09%–0.2% of the Australian population would receive voluntary testing each day.

234

235 According to Australia's vaccine agreements, the Pfizer/BioNTech vaccine (40 million doses
236 available), the Oxford/AstraZeneca vaccine (53.8 million doses available), and the Moderna vaccine
237 (25 million doses available) will account for 33.7%, 45.3%, and 21.0% of COVID-19 vaccination
238 in Australia, respectively⁹. The efficacy of the Pfizer/BioNTech vaccine, the Oxford/AstraZeneca
239 vaccine, and the Moderna vaccine has been reported to be 95% (90.3–97.6%), 67.1% (52.3–77.3%),
240 and 94.1% (89.3–96.8%), respectively^{11–12}. We hence estimated the weighted population
241 vaccination effectiveness to be about 82.2%. Recent studies have shown that the existing vaccines
242 remain equally effective in preventing clinical severities in patients infected with Alpha and Delta
243 variants. Still, there was a slight decrease in effectiveness against infection. The efficacy of the
244 Pfizer/BioNTech vaccine reduced to 93.4% (90.4–95.5%) for Alpha and 87.9% (78.2–93.2%) for
245 Delta variant^{13–15}. The efficacy of the Oxford/AstraZeneca vaccine reduced to 66.1% (54.0–75.0%)
246 for Alpha and 59.8% (28.9–77.3%) for Delta variant^{13–15}. We, therefore, assumed a 2% and 10%
247 reduction in the efficacy of the vaccine against Alpha and Delta.

248

249 **2.3 Transition probability between model compartments**

250 Transition probabilities in the model were derived from published literature and model calibration
251 and were summarized in Supplementary Table 1. We first obtained plausible initial ranges for
252 uncertain parameters through an extensive literature review and then obtained the good-fitting
253 parameter sets by model calibration. Multiple calibration targets were established for model
254 calibration, including the number of daily confirmed cases, the number of daily known-source cases,
255 the number of daily unknown-source cases, and cumulative deaths, from historical outbreaks in
256 Victoria. We calibrated the model by comparing the model predictions with these calibration targets
257 and deducing the most probable values of the set of parameters. In this process, we used a calibration
258 procedure using the genetic algorithm¹⁶. We performed about 1,000,000 simulations in total. In each
259 simulation, one value for each parameter was randomly extracted from its initial range, and a set of
260 input values was formed. With this set of input values, the compartmental model was run to produce
261 the outputs compared with the calibration targets. A goodness-of-fit score was calculated by
262 summing the log-likelihoods. Goodness-of-fit scores were assumed to follow a chi-square
263 distribution with the number of degrees of freedom equal to the number of calibration targets. Based
264 on this distribution, 'good-fitting sets' of model parameters were identified using the likelihood ratio
265 test, comprising those sets that did not produce a non-inferior fit compared with the best-fitting set
266 (using an alpha level of 5%)¹⁷. We ranked the goodness-of-fit scores of the 'good-fitting sets' in
267 ascending order and retained the top 1000 sets of best goodness-of-fit. The best-fitting set was the
268 set with the lowest goodness-of-fit score whose simulated outputs were closest to the calibration
269 targets (Supplementary Table 1). The best-fitting set was introduced into the model as the base-case
270 values of parameters, and the 1000 'good-fitting sets' were used for sensitivity analyses. All analyses
271 and simulations were performed in MATLAB R 2019a.

272


273 **Supplementary Table 1 Transition probabilities between model compartments**

Parameter	Initial range and reference	Best-fitting set
The average probability of being infected per day by contact with a symptomatic infected individual in the household (β)	0.01 – 0.05 ¹⁸	0.0285
Percentage reduction in the average daily probability of being infected by contact with an infectious individual in a public place compared to that of being infected by contact with an infectious individual in households (ρ)	0 – 1	0.60
The reduction in daily transmission probability by contact with an asymptomatic/pre-symptomatic infected individuals (ε)	0 – 1	0.275
The proportion of asymptomatic infections among newly infected individuals (ψ)	0.101 – 0.23 ^{19,20}	0.174
The mean incubation time (days) ($1/v$)	5.0 – 6.7 ²¹	5.8
The interval from symptom onset to isolation in hospital or quarantine (days) ($1/q$)	2 – 8 ²²	4.2
The interval from testing to diagnosis (days) ($1/g$)	1 – 3	2.3
The mean time from infection to recovery for asymptomatic infected individuals (days) ($1/r_1$)	11 – 26 ²³	22
The mean time from diagnosis to recovery for symptomatic infected individuals (days) ($1/r_2$)	11 – 26 ²³	17
Average daily probability of death due to disease during treatment (μ)	0.001 – 0.005 ¹⁸	0.002

274

275 For illustrative purposes, we simulated the historical epidemic trends in Victoria based on the
276 state's total population using the 1000 'good-fitting sets'. We yielded the number of daily
277 confirmed cases, the number of daily unknown-source cases, and the cumulative number of
278 deaths, respectively. The outputs were compared with the corresponding calibration targets, as
279 shown in Supplementary Fig. 5.

280



281

282 **Supplementary Fig. 5 Model outputs of COVID-19 outbreak trends in Victoria (25**
 283 **January 2020 – 12 March 2021)**

284

285 3. Effective reproduction number

286 The effective reproduction number (R_e), the average number of secondary infections caused by a
 287 single infective at a given susceptible fraction, is calculated as the largest eigenvalue of the next
 288 generation matrix $K = F \times V^{-1}$ ^{24–26}, where

289 $F =$

$$290 \begin{bmatrix} (\beta_{EA}^{fam} \cdot c_f + \beta_{EA}^{pub} \cdot c_p(t)) \cdot \psi & (\beta_{EA}^{fam} \cdot c_f + \beta_{EA}^{pub} \cdot c_p(t)) \cdot \psi & (\beta_I^{fam} \cdot c_f + \beta_I^{pub} \cdot c_p(t)) \cdot \psi \\ (\beta_{EA}^{fam} \cdot c_f + \beta_{EA}^{pub} \cdot c_p(t)) \cdot (1 - \psi) & (\beta_{EA}^{fam} \cdot c_f + \beta_{EA}^{pub} \cdot c_p(t)) \cdot (1 - \psi) & (\beta_I^{fam} \cdot c_f + \beta_I^{pub} \cdot c_p(t)) \cdot (1 - \psi) \\ 0 & 0 & 0 \end{bmatrix}$$

291 and

292 $V =$

$$293 \begin{bmatrix} (r_1 + \tau) + \left(\frac{\beta_{EA}^{fam} \cdot \xi \cdot g \cdot (c_f - 1) +}{\beta_{EA}^{pub} \cdot \xi \cdot g \cdot c_p(t)} \right) \cdot \psi \cdot \xi & \left(\frac{\beta_{EA}^{fam} \cdot \xi \cdot g \cdot (c_f - 1) +}{\beta_{EA}^{pub} \cdot \xi \cdot g \cdot c_p(t)} \right) \cdot \psi \cdot \xi & \left(\frac{\beta_I^{fam} \cdot q \cdot (c_f - 1) +}{\beta_I^{pub} \cdot q \cdot c_p(t)} \right) \cdot \psi \cdot \xi \\ \left(\frac{\beta_{EA}^{fam} \cdot \xi \cdot g \cdot (c_f - 1) +}{\beta_{EA}^{pub} \cdot \xi \cdot g \cdot c_p(t)} \right) \cdot (1 - \psi) \cdot \xi & (v + \tau) + \left(\frac{\beta_{EA}^{fam} \cdot \xi \cdot g \cdot (c_f - 1) +}{\beta_{EA}^{pub} \cdot \xi \cdot g \cdot c_p(t)} \right) \cdot (1 - \psi) \cdot \xi & \left(\frac{\beta_I^{fam} \cdot q \cdot (c_f - 1) +}{\beta_I^{pub} \cdot q \cdot c_p(t)} \right) \cdot (1 - \psi) \cdot \xi \\ 0 & -v & q \end{bmatrix}$$

294

295 The effective reproduction number under vaccination R_v is the number of secondary cases caused
 296 by one primary case introduced into a certain proportion of the vaccinated population^{27,28}. We
 297 assumed that individuals who receive the vaccine and develop an immune response would no longer
 298 be infected over a period of time. Thus, R_v was expressed as:

$$R_v = (1 - \theta \cdot p) \cdot R_e \quad (7)$$

299


300 Where θ denotes the efficacy of the vaccine and p denotes the vaccination coverage.

301

302 **4. Estimation of undocumented cases**

303 Undocumented cases represented a potential risk of further community transmission of SARS-CoV-
304 2. Three types of infections were considered 'undocumented' in our model. They were asymptomatic
305 infections, pre-symptomatic infections, and symptomatic infections before diagnosis. The number
306 of undocumented cases in historical outbreaks in Victoria was estimated based on the compartmental
307 model and was shown in Supplementary Fig. 6. As can be seen, the cumulative number of cases
308 rose at the fastest rate when the number of active undocumented cases reached a peak.

309



310


311 **Supplementary Fig. 6 Model outputs of undocumented cases (including asymptomatic**
312 **infected individuals, pre-symptomatic infected individuals, and symptomatic infected**
313 **individuals before diagnosis) in historical outbreaks in Victoria (25 January 2020 – 12**
314 **March 2021)**

315

316 **5. Association between the number of undocumented cases and the** 317 **number of daily reported cases**

318 Supplementary Fig. 7 demonstrated the potential reasons for cases being identified as unknown
319 sources. Supplementary Fig. 8 showed the relationship between the number of daily unknown-
320 source cases and the number of active asymptomatic infections, and the relationship between the
321 number of daily known-source cases and the number of active pre-symptomatic/symptomatic
322 infections. The number of active undocumented cases was estimated from the model, and the
323 number of daily cases was obtained from reported data. Using the 1000 'good-fitting sets' of model
324 parameters, we calculated the interquartile range of the slope of the linear relationships, which was
325 shown in Supplementary Fig. 9.



326



327


328 **Supplementary Fig. 7 The reasoning process for the source of confirmed cases**

329



330

331 **Supplementary Fig. 8 The linear relationships between the number of daily unknown-**
 332 **source cases and the number of model-estimated asymptomatic infections, and between the**
 333 **number of daily known-source cases and the number of model-estimated pre-**
 334 **symptomatic/symptomatic infections**
 335



336

337 **Supplementary Fig. 9 Sensitivity analysis for the linear relationships**

338

339 **6. Predicted number of reported cases over the next 7 days**

340 Based on the definition of R_e , i.e., the number of secondary cases generated by a single infectious
 341 case, we multiplied R_e with the number of undocumented cases to obtain the total number of
 342 secondary cases caused by the current source of infection during the average infectious period.

343

344 We estimated the average infectious period for individuals infected with SARS-COV-2 as follows.
 345 Previous studies have indicated that the mean incubation period for pre-symptomatic infected
 346 individuals (who later became symptomatic) was approximately 5.8 (95% CI 5.0–6.7) days²¹, and
 347 the interval from symptom onset to isolation in hospital or quarantine was about 5.6 (IQR 2–8)
 348 days²². Therefore, the average infectious period for a pre-symptomatic case was approximately 11.4
 349 days. In contrast, asymptomatic infected individuals who never presented any symptoms would
 350 additionally experience an asymptomatic recovery period of 17 ± 4 (range 11–26) days²³, resulting
 351 in an overall infectious period (i.e. incubation period plus asymptomatic recovery period) of 22.8
 352 days. Given the proportion of asymptomatic cases among infected cases is 17% (95% CI 14–20%)¹⁹,
 353 the weighted average infectious period of a SARS-COV-2 infected individual was estimated to be
 354 about 14 days.


355

356 According to the linear relationships (Supplementary Fig. 8–9), we estimated the number of

357 undocumented cases in the populations based on the number of daily reported cases. Then, the
358 overall number of secondary cases over the next 14 days was obtained by multiplying R_e with the
359 number of undocumented cases. We divided this number by 2 to obtain the number of reported cases
360 over the next 7 days.
361

362 7. Model validation

363 Using the method described above, we predicted the number of reported cases in the next 7 days
364 based on the average number of daily cases in the first three days of historical epidemic data and
365 formed prediction curves for epidemic trends in Victoria, New South Wales, the Australian Capital
366 Territory, and Western Australia, respectively. Supplementary Fig. 10 showed the comparison
367 between the projected number of cases over the next 7 days with the actual number of reported cases
368 over a 7-day period in each of Victoria, New South Wales, Australian Capital Territory, and Western
369 Australia, for the period 25 January 2020 –12 March 2021. It can be seen that the model predictions
370 matched well with the actual epidemic trends, with an R-squared of 0.99, 0.85, 0.74, and 0.87,
371 respectively.
372



373
374 **Supplementary Fig. 10 Model predictions of COVID-19 outbreak trends in Victoria, New**
375 **South Wales, the Australian Capital Territory, and Western Australia (25 January 2020 –12**
376 **March 2021)**

377 **References:**

- 378 1. Centers for Disease Control and Prevention. Case investigation & contact tracing guidance:
379 contact tracing for COVID-19. [https://www.cdc.gov/coronavirus/2019-ncov/php/contact-](https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/contact-tracing.html)
380 [tracing/contact-tracing-plan/contact-tracing.html](https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/contact-tracing.html) (2021).
- 381 2. Dyani L. Where COVID contact-tracing went wrong. *Nature*.
382 [https://media.nature.com/original/magazine-assets/d41586-020-03518-4/d41586-020-03518-](https://media.nature.com/original/magazine-assets/d41586-020-03518-4/d41586-020-03518-4.pdf)
383 [4.pdf](https://media.nature.com/original/magazine-assets/d41586-020-03518-4/d41586-020-03518-4.pdf) (2020).
- 384 3. Alsubaie, H., Goldenberg, M., Grantcharov, T. Quantifying recall bias in surgical safety: a
385 need for a modern approach to morbidity and mortality reviews. *Can J Surg*. **62**, 39–43
386 (2019).
- 387 4. Google. COVID-19 Community Mobility Reports.
388 <https://www.google.com/covid19/mobility> (2021).
- 389 5. Fitzhugh Mullan Institute for Health Workforce Equity, the George Washington University.
390 Contact tracing workforce estimator. <https://www.gwhwi.org/estimator-613404.html> (2020).
- 391 6. Chu, D.K., et al. Physical distancing, face masks, and eye protection to prevent person-to-
392 person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis.
393 *Lancet*. **395**,1973–1987 (2020).
- 394 7. Howard, J., et al. An evidence review of face masks against COVID-19. *Proc Natl Acad Sci*
395 *U S A*. **118**, e2014564118 (2021).
- 396 8. Institute for Health Metrics and Evaluation. COVID-19 Projections-Australia.
397 <https://covid19.healthdata.org/australia?view=cumulative-deaths&tab=trend> (2021).
- 398 9. Australia’s vaccine agreements. [https://www.health.gov.au/node/18777/australias-vaccine-](https://www.health.gov.au/node/18777/australias-vaccine-agreements)
399 [agreements](https://www.health.gov.au/node/18777/australias-vaccine-agreements) (2021).
- 400 10. Polack, F.P., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J*
401 *Med*. **383**, 2603–2615 (2020).
- 402 11. Voysey, M., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
403 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa,
404 and the UK. *Lancet*. **397**, 99–111 (2021).
- 405 12. Baden, L.R., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J*
406 *Med*. **384**, 403–416 (2021).
- 407 13. Stowe, J., et al. Effectiveness of COVID-19 vaccines against hospital admission with the
408 Delta variant. PHE national [https://khub.net/web/phe-national/public-library/-](https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZIEig/view/479607266)
409 [/document_library/v2WsRK3ZIEig/view/479607266](https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZIEig/view/479607266) (2021).
- 410 14. Lopez Bernal, J., et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.
411 Preprint at MedRxiv: <https://doi.org/10.1101/2021.05.22.21257658> (2021).
- 412 15. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland:
413 demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*. **397**, 2461–2462
414 (2021).
- 415 16. John, M. Genetic algorithms for modelling and optimisation. *J Comput Appl Math*. **184**, 205–
416 222 (2005).
- 417 17. Kim, J.J., et al. Multiparameter calibration of a natural history model of cervical cancer. *Am*
418 *J Epidemiol*. **166**, 137–50 (2007).
- 419 18. Shen, M., et al. Assessing the effects of metropolitan-wide quarantine on the spread of

- 420 COVID-19 in public space and households. *Int J Infect Dis.* **96**, 503–505 (2020).
- 421 19. He, J., Guo, Y., Mao, R. & Zhang, J. Proportion of asymptomatic coronavirus disease 2019: a
422 systematic review and meta-analysis. *J Med Virol.* **93**, 820–830 (2021).
- 423 20. Byambasuren, O., et al. Estimating the extent of true asymptomatic COVID-19 and its
424 potential for community transmission: systematic review and meta-analysis. *JAMMI.* **5**, 223–
425 234 (2020).
- 426 21. McAloon, C., et al. Incubation period of COVID-19: a rapid systematic review and meta-
427 analysis of observational research. *BMJ open.* **10**, e039652 (2020).
- 428 22. Ng, Y., et al. Evaluation of the effectiveness of surveillance and containment measures for the
429 first 100 patients with COVID-19 in Singapore - January 2-February 29, 2020. *MMWR Morb*
430 *Mortal Wkly Rep.* **69**, 307–311 (2020).
- 431 23. Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from
432 Coronavirus Disease 2019 (COVID-19). *Radiology.* 2020; 295(3):715–721.
- 433 24. Cintrón-Arias, A., Castillo-Chávez, C., Bettencourt, L.M., Lloyd, A.L. & Banks, H.T. The
434 estimation of the effective reproductive number from disease outbreak data. *Math Biosci Eng.*
435 **6**, 261–282 (2009).
- 436 25. Diekmann, O., Heesterbeek, J.A. & Metz, J.A. On the definition and the computation of the
437 basic reproduction ratio R_0 in models for infectious diseases in heterogeneous populations. *J*
438 *Math Biol.* **28**, 365–82 (1990).
- 439 26. Yang, W. Transmission dynamics of and insights from the 2018–2019 measles outbreak in
440 New York City: a modeling study. *Sci Adv.* **6**, eaaz4037 (2020).
- 441 27. Scherer, A. & McLean, A. Mathematical models of vaccination. *Br Med Bull.* **62**, 187–99
442 (2002).
- 443 28. Farrington, C.P. On vaccine efficacy and reproduction numbers. *Math Biosci.* **185**, 89–109
444 (2003).